Quarterly report · Q2

Period2023-12-01 → 2024-05-31
Filed2024-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥4.2bn2023-12-01 → 2024-05-31Cons.Net sales
Revenue¥8.6bn2022-12-01 → 2023-11-30Cons.Net sales (5-year summary)
Revenue¥4.2bn2022-12-01 → 2023-05-31Cons.Net sales
Operating income¥202m2023-12-01 → 2024-05-31Cons.Operating income
Operating income¥156m2022-12-01 → 2023-05-31Cons.Operating income
Ordinary income¥212m2023-12-01 → 2024-05-31Cons.Ordinary income
Ordinary income¥345m2022-12-01 → 2023-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥156m2022-12-01 → 2023-05-31Cons.Ordinary income
Profit before tax¥252m2023-12-01 → 2024-05-31Cons.Income before income taxes
Profit before tax¥155m2022-12-01 → 2023-05-31Cons.Income before income taxes
Net income (owners)¥193m2023-12-01 → 2024-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥256m2022-12-01 → 2023-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥121m2022-12-01 → 2023-05-31Cons.Profit loss attributable to owners of parent
Net income¥193m2023-12-01 → 2024-05-31Cons.Profit loss
Net income¥121m2022-12-01 → 2023-05-31Cons.Profit loss
Total assets¥8.0bnat 2024-05-31Cons.Assets
Total assets¥8.3bnat 2023-11-30Cons.Assets
Total assets¥8.0bnat 2023-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.3bnat 2024-05-31Cons.Liabilities
Total liabilities¥5.7bnat 2023-11-30Cons.Liabilities
Net assets / equity¥2.7bnat 2024-05-31Cons.Net assets
Net assets / equity¥2.6bnat 2023-11-30Cons.Net assets
Net assets / equity¥2.5bnat 2023-05-31Cons.Net assets (5-year summary)
Cash and deposits¥947mat 2024-05-31Cons.Cash and deposits
Cash and deposits¥1.0bnat 2023-11-30Cons.Cash and deposits
Cash & equivalents¥947mat 2024-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.0bnat 2023-11-30Cons.Cash and cash equivalents
Cash & equivalents¥999mat 2023-05-31Cons.Cash and cash equivalents
Cash & equivalents¥911mat 2022-11-30dCons.Cash and cash equivalents
Operating cash flow¥90m2023-12-01 → 2024-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥470m2022-12-01 → 2023-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥223m2022-12-01 → 2023-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥96m2023-12-01 → 2024-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥370m2022-12-01 → 2023-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥217m2022-12-01 → 2023-05-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥101m2023-12-01 → 2024-05-31Cons.Net cash provided by used in financing activities
Financing cash flow¥21m2022-12-01 → 2023-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥80m2022-12-01 → 2023-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥158.382023-12-01 → 2024-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥117.592024-03-01 → 2024-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥209.882022-12-01 → 2023-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥99.172022-12-01 → 2023-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.392023-03-01 → 2023-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio34.2%at 2024-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2023-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.1%at 2023-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2023-12-01 → 2024-05-31¥187m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2023-12-01 → 2024-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-12-01 → 2024-05-31¥202m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2022-12-01 → 2023-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2022-12-01 → 2023-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2022-12-01 → 2023-05-31¥141m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2022-12-01 → 2023-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2022-12-01 → 2023-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2022-12-01 → 2023-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2022-12-01 → 2023-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-12-01 → 2023-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-12-01 → 2023-05-31¥156m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 480
ItemContextValueUnit
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember201000
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.166
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember121000
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.099
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember43000
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.035
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember28000
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.023
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember25000
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.021
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember25000
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.021
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember17000
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.014
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember17000
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.014
Number of shares heldCurrentQuarterInstant519000
Shareholding ratioCurrentQuarterInstant0.427
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember2500
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember1213100
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember12131
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember4400
Number of shares issued shares voting rightsCurrentQuarterInstant1220000
Number of voting rights issued shares voting rightsCurrentQuarterInstant12131
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2500
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2500
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0020
Number of shares held in own name treasury shares etcCurrentQuarterInstant2500
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant2500
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0020
Cash and depositsPrior1YearInstant1043816000JPY
Cash and depositsCurrentQuarterInstant946977000JPY
Notes and accounts receivable tradePrior1YearInstant3080334000JPY
Notes and accounts receivable tradeCurrentQuarterInstant2705324000JPY
Merchandise and finished goodsPrior1YearInstant1095822000JPY
Merchandise and finished goodsCurrentQuarterInstant1213540000JPY
Work in processPrior1YearInstant412440000JPY
Work in processCurrentQuarterInstant377039000JPY
Raw materials and suppliesPrior1YearInstant367593000JPY
Raw materials and suppliesCurrentQuarterInstant536007000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-11-30pass
balance sheet identityconsolidated 2024-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-11-30pass
statement vs summary · net assetsconsolidated 2024-05-31pass
statement vs summary · net income attributable to parentconsolidated 2022-12-01/2023-05-31pass
statement vs summary · net income attributable to parentconsolidated 2023-12-01/2024-05-31pass
statement vs summary · operating cash flowconsolidated 2022-12-01/2023-05-31pass
statement vs summary · operating cash flowconsolidated 2023-12-01/2024-05-31pass
statement vs summary · revenueconsolidated 2022-12-01/2023-05-31pass
statement vs summary · revenueconsolidated 2023-12-01/2024-05-31pass
statement vs summary · total assetsconsolidated 2023-11-30pass
statement vs summary · total assetsconsolidated 2024-05-31pass